297
Participants
Start Date
February 28, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
July 31, 2014
BMS-986001
Capsules, Oral, 100 mg, Once daily, At least 48 weeks
BMS-986001
Capsules, Oral, 200 mg, Once daily, At least 48 weeks
BMS-986001
Capsules, Oral, 400 mg, Once daily, At least 48 weeks
Placebo matching with BMS-986001
Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Tenofovir
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Local Institution, Cercado
Local Institution, Barranco
Local Institution, San Martín de Porres
Local Institution, Budapest
Local Institution, Liverpool
Local Institution, Darlinghurst
Local Institution, Soweto
Local Institution, Johannesburg
Local Institution, Dundee
Local Institution, Melbourne
Local Institution, Durban
Local Institution, Durban KZN
Local Institution, Cape Town
Local Institution, Cape Town
Local Institution, Bloemfontein
Local Institution, New York
Local Institution, Bangkok
Local Institution, Bangkok
Jacobi Medical Center, The Bronx
Local Institution, Bangkok
Local Institution, Nontaburi
University At Buffalo, Buffalo
University Of Pennsylvania, Philadelphia
Local Institution, Washingtondc
Local Institution, Madrid
Local Institution, Charlotte
Local Institution, Columbia
Aids Research Consortium Of Atlanta, Atlanta
Orlando Immunology Center, Orlando
Triple O Medical Services, P.A., West Palm Beach
Local Institution, Khon Kaen
Indiana University, Indianapolis
Clinic 42 And International Travel Clinic, Minneapolis
Local Institution, Lyon
North Texas Infectious Disease Consultants, Dallas
Tarrant County Infectious Disease Associates, Fort Worth
Therapeutic Concepts, P.A., Houston
St. Hope Foundation, Bellaire
Central Texas Clinical Research, Austin
Uc Davis Medical Center, Sacramento
Local Institution, Santiago
Local Institution, Santiago
Local Institution, Ciudad de Buenos Aires
Local Institution, Vancouver
Local Institution, Montreal
Local Institution, Montreal
Local Institution, Bogota
Local Institution, Iquitos
Local Institution, Mexico City
Local Institution, Badalona
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY